Open Access<p>High PD-L1 Expression is Associated with Unfavorable Clinical Outcome in <em>EGFR</em>-Mutated Lung Adenocarcinomas Treated with Targeted Therapy</p>
Author(s) -
Byung Woo Yoon,
Betty L. Chang,
Seung Hyeun Lee
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s271011
Subject(s) - medicine , hazard ratio , t790m , lung cancer , oncology , pd l1 , adenocarcinoma , epidermal growth factor receptor , population , gastroenterology , immunotherapy , cancer , confidence interval , gefitinib , environmental health
Although programmed death-ligand 1 (PD-L1) expression is widely accepted as a predictive and prognostic biomarker in immunotherapy, its implications in lung cancer patients with driving mutations are still unclear. The objective of this study is to determine the association between PD-L1 expression and treatment outcome in epidermal growth factor receptor ( EGFR )-mutated lung cancer treated with tyrosine kinase inhibitors (TKIs).